L&C Bio Overview
- Year Founded
-
2011
- Status
-
Public
- Employees
-
142
- Stock Symbol
-
290650
- Investments
-
7
- Share Price
-
$15.10
- (As of Friday Closing)
L&C Bio General Information
Description
L&C BIO Co Ltd manufactures and distributes medical equipment.
Contact Information
Website
www.lncbio.co.krCorporate Office
- Rooms 605, 606, and 607, 474 Dunchon
- Jungwon
- Seongnam, Gyeonggi 13229
- South Korea
Corporate Office
- Rooms 605, 606, and 607, 474 Dunchon
- Jungwon
- Seongnam, Gyeonggi 13229
- South Korea
L&C Bio Stock Performance
As of 13-Nov-2026, L&C Bio’s stock price is $15.10. Its current market cap is $919M with 60.9M shares.
(As of Friday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $15.10 | $16.05 | $14.18 - $41.74 | $919M | 60.9M | 510K | -$2.06 |
L&C Bio Financials Summary
As of 30-Jun-2026, L&C Bio has a trailing 12-month revenue of $80.1M.
|
In Thousands, USD |
TTM 30-Jun-2026 | FY 2025 31-Dec-2025 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 |
|---|---|---|---|---|
| EV | 1,598,370 | 1,077,230 | 415,714 | 503,775 |
| Revenue | 80,140 | 60,062 | 52,793 | 50,424 |
| EBITDA | (93,092) | (103,466) | 108,646 | 56,269 |
| Net Income | (102,953) | (97,092) | 103,776 | 36,989 |
| Total Assets | 309,415 | 317,107 | 320,542 | 203,487 |
| Total Debt | 41,327 | 64,027 | 84,116 | 63,735 |
L&C Bio Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
L&C Bio Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
L&C Bio Patents
L&C Bio Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2026221465-A1 | Negative pressure wound therapy device and method using high-concentration oxygen gas | Pending | 17-Apr-2025 | ||
| WO-2026141969-A1 | Periodontal tissue regeneration-inducing material comprising acellular dermal matrix and method for preparing same | Pending | 27-Dec-2024 | ||
| WO-2026111453-A1 | Soft tissue filling composition including particulated acellular dermal matrix | Pending | 22-Nov-2024 | ||
| WO-2025095190-A1 | Bone scaffold using 3d printing technology and method for manufacturing same | Inactive | 02-Nov-2023 | ||
| US-20230310142-A1 | Retromammary breast-conserving surgery with diced acellular dermal matrix for volume replacement in breast cancer | Pending | 01-Apr-2022 | A61F2/12 |
L&C Bio Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
L&C Bio Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
L&C Bio Investments & Acquisitions (7)
L&C Bio’s most recent deal was a Secondary Transaction - Private with Ains Biotechnology. The deal was made on 10-Feb-2025.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Ains Biotechnology | 10-Feb-2025 | Secondary Transaction - Private | Therapeutic Devices | ||
| LNC Bio (Patent Rights for MegaDerm Star in Korea) | 24-Sep-2024 | Corporate Asset Purchase | Buildings and Property | ||
| L&C BIO Company (Patents for Acellular Nerve Graft and Manufacturing Method ) | 20-Oct-2023 | Corporate Asset Purchase | Buildings and Property | ||
| Curexo | 30-Jun-2022 | PIPE | Surgical Devices | ||
| NanoFocusRay | 18-Feb-2022 | Merger/Acquisition | Diagnostic Equipment |
L&C Bio ESG
Risk Overview
Risk Rating
Updated November, 04, 2026
35.86 | High Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 13,585
Rank
Percentile
Healthcare
Industry
of 590
Rank
Percentile
Medical Devices
Subindustry
of 209
Rank
Percentile
L&C Bio Affiliates
Subsidiaries (1)
| Name | Industry | Location | Year Founded |
|---|---|---|---|
| Ains Biotechnology | Suzhou, China | 2020 |
L&C Bio FAQs
-
When was L&C Bio founded?
L&C Bio was founded in 2011.
-
Where is L&C Bio headquartered?
L&C Bio is headquartered in Seongnam, South Korea.
-
What is the size of L&C Bio?
L&C Bio has 142 total employees.
-
What industry is L&C Bio in?
L&C Bio’s primary industry is Diagnostic Equipment.
-
Is L&C Bio a private or public company?
L&C Bio is a Public company.
-
What is L&C Bio’s stock symbol?
The ticker symbol for L&C Bio is 290650.
-
What is the current stock price of L&C Bio?
As of 13-Nov-2026 the stock price of L&C Bio is $15.10.
-
What is the current market cap of L&C Bio?
The current market capitalization of L&C Bio is $919M.
-
What is L&C Bio’s current revenue?
The trailing twelve month revenue for L&C Bio is $80.1M.
-
What is L&C Bio’s annual earnings per share (EPS)?
L&C Bio’s EPS for 12 months was -$2.06.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
